Jason Kritzer

Jason Kritzer asked how to think about the quarter-over-quarter clinical volume growth for 2026, given the 6,200 clinical tests delivered in Q4 2025, and if a linear growth rate is appropriate.

Answer

Aaron Tachibana, Chief Financial and Chief Operating Officer, suggested that linearizing the Q4 2025 volume might get close, but noted seasonality, with Q2 and Q4 typically being the strongest quarters. Chris Hall, Chief Executive Officer and President, confirmed this common seasonality due to vacations, holidays, and Q1 weather. Jason Kritzer also asked about the competitive landscape, new entrants, consolidation, and how Personalis plans to gain share against larger players. Chris Hall emphasized Personalis' proven execution, pioneering ultrasensitive products, commitment to staying ahead, strategic partnership with Tempus, traction from over 30 ongoing studies, and significant R&D investment, positioning them as a major player with momentum and leadership in data.

Jason Kritzer asked how to project the Q-over-Q clinical volume growth for 2026, given the 6,200 clinical tests delivered in Q4 2025. He also inquired about the current competitive landscape, including new entrants and consolidation, and Personalis's strategy to gain market share against larger players.

Answer

Aaron Tachibana, CFO and COO, suggested that linearizing the Q4 2025 volume might provide a close estimate, with Q2 and Q4 typically being stronger due to seasonality. Chris Hall, CEO and President, stated that Personalis has proven its execution, is focused on pioneering ultrasensitive products, and aims to stay ahead. He highlighted their alignment with Tempus for commercial infrastructure, traction from 30+ ongoing studies, and emergence as one of the few major players with more than two Medicare coverages, positioning them well to maintain leadership.